Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in over 240 years of distinguished history in Japan.

We have presence in approximately 80 countries, with leading positions in Japan and the U.S., respectively the third and first largest pharmaceutical markets in the world. We will deliver highly innovative medicines and transformative care for more people globally.

For more than 230 years, Takeda has developed its business with integrity while undergoing a process of continuous transformation.

Takeda began operations in 1781 when Chobei Takeda I started a business selling traditional Japanese and Chinese medicines in Doshomachi, Osaka. Takeda has been supplying pharmaceuticals for over 230 years, during which time we have developed a strong commitment to the highest ethical standards and a strong sense of mission. We have made constant efforts to improve our relationship with society over this time. As we move forward, we will continue to fulfil our responsibilities as a global Biopharmaceutical company.

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

AstraZeneca is a global, science-led pharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Our Malaysia operations - AstraZeneca Malaysia Sdn Bhd - was established in 1981 and it uniquely hosts the Commercial Business, Site Management and Monitoring and Global Financial Services, demonstrating our commitment to bringing in science and innovation to help patients and boosting the employment of skilled talent in the country.

Our therapy areas in Malaysia are Oncology, Cardiovascular, Renal and Metabolism (CVRM), Respiratory and Immunology (R&I), Vaccines and Immune Therapies (V&I) and Rare Diseases.

In Malaysia, we are committed to tackling significant healthcare challenges by harnessing the power of science to transform outcomes for people, society and the planet. Through the commercialisation of prescription medicines, we aim to deliver innovative medicines that address unmet medical needs, transforming outcomes of patients. We are increasing access to healthcare for patients and making healthcare systems more resilient. We are doing all this by harnessing digital technologies and AI, while contributing sustainably to people, society and planet.

Bristol Myers Squibb is a biopharmaceutical specialist. It is committed to finding and developing new innovations to help patients with serious illnesses. Better quality of life, Bristol Myers Squibb. Focus on driving scientific and academic excellence, as well as caring and rigorously developing innovative, quality to meet patient needs, and trying to make our innovations benefit the wider patients by trying to push forward and support policies on equality, equality and fairness in health services. We care about providing information about neutral and accurate products.

Novartis had a long heritage and legacy in Malaysia. Established in 1971, we are a leading multinational company employing close to 600 associates who work in the Novartis International division and Novartis Corporate Center, Kuala Lumpur. Through our over 50-year presence in Malaysia, Novartis Malaysia continues to deliver on its corporate purpose of reimagining medicine to improve and extend the lives of over 32 million Malaysians.

In 2022, Novartis Malaysia was recognized as Sponsor of the Year by Clinical Research Malaysia for initiating 24 new clinical trials. We also have a proven track record of expanding access to our innovative medicines in private or public via collaborations with the Ministry of Health Malaysia. Through these collaborations, Novartis has succeeded in touching the lives of more than 1.2 million Malaysian patients.

Novartis Malaysia’s office is located at Plaza Imazium, Damansara Utama, Petaling Jaya. Novartis Malaysia occupies 2 floors and was one of 20 offices in Malaysia to be LEED Gold certified and the first office to be WELL Silver certified.

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders.

Roche has been present in Malaysia since the 1950s. Since then, Roche has established its operations to include Roche (Malaysia) Sdn. Bhd., the pharmaceutical business; Roche Diagnostics (Malaysia) Sdn. Bhd., the diagnostics business and Roche Services (Asia Pacific) Sdn. Bhd. With a total staff strength of over 1,000, Roche has grown into one of the leading healthcare companies in Malaysia that provides holistic healthcare solutions to healthcare practitioners and patients. For more information, please visit www.roche.com.my

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en.

Founded in 2019, Auxi Therapeutics Sdn Bhd is a company specializing in providing variety of T-cell-based immunotherapies for cancer treatment. We provide cutting-edge biotechnology “products” to hospitals/patients seeking better, genomic answers for cancer. Our suite of T cell-based Immunotherapy and services are highly accurate, personal and easy to practice in local settings.

We are a team of innovative scientists and healthcare assistance that envision a world without cancer that is enabled by empowered healthcare providers who have access to the right treatment with highly targeted results at the right time to inform cancer care.

Celltrion Healthcare is a global biopharmaceutical company based in South Korea. We offer biosimilar products to patients around the world, with presence in 110 countries. Our rituximab biosimilar have been widely prescribed in Europe, US, and other parts of the world, getting positive experience and reviews from doctors, patients, and other relevant agencies.

Who We Are?

'Good Health’ is always our goal. We see medicines not just as molecules, but as means to help patients regain their health. As a leader in the pharmaceutical industry, we realize our unique role; we have the ethical and moral imperative to ensure good health can be delivered to those who need it, and to promote wellness among them. 'Can't Wait’ reflects our commitment to act with speed to find innovative solutions that address the unmet needs of patients, and to accelerate access to much-needed medicines for people around the world.

As a Malaysian pharmaceutical company, Duopharma Biotech Berhad believes in creating equity in healthcare for all Malaysians – empowering people to live a better life via accessible and affordable healthcare. Through our professional expertise and resources, we aim to offer every person access to medicines, health supplements and healthcare tools- all proudly made in Malaysia.

KYAN Technologies Pte Ltd is a leader in the field of functional precision medicine, committed to addressing unmet needs and gaps in cancer treatment through small data AI and the phenotypic perturbation of biological models including patient samples and organoids. KYAN’s flagship platform, Optim.AI™, has been applied in clinical studies for non-hodgkin lymphoma, acute myeloid leukemia and soft tissue sarcomas. Through clinical collaborations, KYAN also looks to expand the applicability of its technology into other solid cancer indications, including pancreatic cancer and breast cancer. KYAN is licensed by the Singapore Ministry of Health as a clinical laboratory.

Plutonet is a medical biotechnology company focussing on cell and gene-based immunotherapy, located within the Multimedia Super Corridor (MSC) at Bio-X Centre, Cyberjaya, a high-tech science and research-based development centre.

We operate from Malaysia's first Biosafety Level 2 (BSL-2) cGMP facility, in accordance to PIC/S standards by the National Pharmaceutical Regulatory Agency (NPRA), a division of Ministry of Health, Malaysia.

Our team is dedicated to the development, production, and commercialisation of cell and gene-based immuno-therapeutic products, with a primary focus on CAR T-cells therapy for the treatment of blood cancers and tumours.